A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
E303-1001
Phase 1 other active
Quick answer
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors for advanced refractory solid tumors is a Phase 1 program (other) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Samsung Bioepis NL B.V.
- Indication
- advanced refractory solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active